Compare INUV & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | SNTI |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 29.8M |
| IPO Year | 1996 | 2021 |
| Metric | INUV | SNTI |
|---|---|---|
| Price | $1.89 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $11.00 | $8.50 |
| AVG Volume (30 Days) | ★ 202.8K | 142.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,209,305.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $0.36 | $0.77 |
| 52 Week High | $6.27 | $3.88 |
| Indicator | INUV | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 46.48 |
| Support Level | $1.82 | $0.78 |
| Resistance Level | $1.99 | $0.99 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 27.03 | 20.75 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).